Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juli 2026 09:00 ET | Quelle: Muscular Dystrophy Association

Registration Open for 2027 MDA Clinical & Scientific Conference, Showcasing Rapid Advances in Neuromuscular Research, Care, and AI-Driven Innovation

New York, July 29, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced that registration is now open for the 2027 MDA Clinical & Scientific Conference, taking place...
29. Juli 2026 08:30 ET | Quelle: Clene Inc.

Clene to Present at The Canaccord 46th Annual Growth Conference

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
09. Juni 2026 12:47 ET | Quelle: AB Science

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

PRESS RELEASE AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been...
09. Juni 2026 12:47 ET | Quelle: AB Science

AB Science présentera, lors du congrès annuel 2026 de l'ENCALS, les données de survie issues du programme clinique du masitinib dans la SLA

COMMUNIQUÉ DE PRESSE AB SCIENCE PRÉSENTERA, LORS DU CONGRÈS ANNUEL 2026 DE L'ENCALS, LES DONNÉES DE SURVIE ISSUE DU PROGRAMME CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Le...
02. Juni 2026 07:02 ET | Quelle: Pasithea

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
22. Mai 2026 07:00 ET | Quelle: AC Immune SA

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients...
12. März 2026 07:50 ET | Quelle: Muscular Dystrophy Association

The 2026 MDA Clinical & Scientific Conference Highlights Breakthroughs in Neuromuscular Research, Innovative Therapies, and Patient Care

Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees...
24. Februar 2026 07:00 ET | Quelle: AC Immune SA

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of...
19. Februar 2026 03:30 ET | Quelle: Custom Market Insights

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.
18. Februar 2026 06:00 ET | Quelle: CervoMed Inc.

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

CervoMed's neflamapimod has been selected for the U.K.’s EXPERTS-ALS platform to rapidly evaluate it in ALS

Nächste Seite